---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Dosing and administration questions"
description: "Dosing and administration questions on Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing. Questions: What is the Enhertu dose for HER2-low breast cancer? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/dosing-and-administration"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Dosing and administration questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)

Dosing and administration questions that apply to every indication of Enhertu are on [Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Dosing and administration](https://www.evicenter.com/medical-information/enhertu/dosing-and-administration).

## Dosing

<a id="enhertu-dose"></a>

### What is the Enhertu dose for HER2-low breast cancer?

> “Table 1: Recommended Dosage
> Indication 
> Recommended 
> ENHERTU Dosage 
> Duration of Therapy”

Source: [ENHERTU: Prescribing information, page 3, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=3)

> “HER2-Positive, HER2-Low, or 
> HER2- Ultralow Metastatic 
> Breast Cancer, 
> HER2-Mutant Unresectable 
> or Metastatic NSCLC, and 
> HER2-Positive (IHC 3+)  
> Unresectable or Metastatic 
> Solid Tumors as monotherapy
> ENHERTU 5.4 mg/kg 
> every 3 weeks 
> Until disease progression 
> or unacceptable toxicity”

Source: [ENHERTU: Prescribing information, page 3, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=3)

> “ADMINISTER: ENHERTU is administered as an IV infusion once every 3 weeks (21-day cycle)<sup>1</sup>”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=ADMINISTER%3A%20ENHERTU%20is%20administered%20as,once%20every%203%20weeks%20%2821%2Dday)

Note: Table 1 columns are indication, recommended ENHERTU dosage, and duration of therapy; the row shown covers HER2-low and HER2-ultralow metastatic breast cancer together with other indications that use the same monotherapy dose.

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/safety)
- [Guidelines](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/guidelines)
